Commercialized products

EGRIFTA SV® (tesamorelin for injection)

EGRIFTA SV® is a new formulation of tesamorelin which requires a smaller volume of administration and a smaller needle compared to the original formulation. EGRIFTA SV® comes in a single vial, instead of two, and can be stored at room temperature.   EGRIFTA SV® (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people living with HIV who have lipodystrophy.   Lipodystrophy affects the redistribution of fat that includes the accumulation and loss of fat in certain parts of the human body. The excess fat in the abdomen exerts pressure in the abdomen in the internal organs. The consequences of lipodystrophy are therefore numerous and serious.   It is estimated that more than 70,000 people living with HIV in the United States also have lipodystrophy.   It is important to note that lipodystrophy has nothing to do with the subcutaneous fat found in obese people.